

	Healthcare Provider's Name (e.g., neurologist)	Healthcare Provider's Name (e.g., primary care provider)
Name:		
Phone Number:		
Fax Number: (for medical records or lab tests)		
Reference ID: 3912872		

For more information on LEMTRADA, including important risks, please refer to the Prescribing Information and/or [www.LEMTRADA.com](http://www.LEMTRADA.com)

For information on LEMTRADA or the LEMTRADA REMS Program, call **1-855-676-6326**

**genzyme**  
A SANOFI COMPANY

**LEMTRADA**  
alemtuzumab<sup>12mg</sup><sub>iv</sub>

LEMTRADA and Genzyme are registered trademarks of Genzyme Corporation.  
©2015 Genzyme Corporation, a Sanofi company. All rights reserved. US.MS.LEM.14.10.001-v2

**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>

**Patient Safety Information Card**

*Please show this card to all emergency workers  
and healthcare providers.*

## Important information to know about LEMTRADA

<<insert your name>>

has been treated with LEMTRADA, a treatment for multiple sclerosis (MS), which lowers the number of circulating white blood cells for a period of time after treatment and also affects the immune system. Therefore, the patient is part of a laboratory monitoring program that continues for 4 years after his/her last treatment.

Reference ID: 3912872

**LEMTRADA**  
alemtuzumab<sup>12mg</sup><sub>IV</sub>

## LEMTRADA treatment can increase the risk of:

### Autoimmune conditions such as:

- > A bleeding problem called immune thrombocytopenia (ITP)
- > Other blood disorders (including neutropenia, hemolytic anemia, and pancytopenia)
- > Disorders of the thyroid gland (hypo/hyperthyroidism)
- > Kidney disorders (nephropathies, including anti-glomerular basement membrane [anti-GBM] disease)

### Infusion reactions (may occur more than 24 hours after the infusions), such as:

- > Hypersensitivity reactions (including anaphylaxis)
- > Fever
- > Hives
- > Irregular heartbeat
- > Nausea
- > Chest pain
- > Low blood pressure

### Malignancies such as:

- > Thyroid cancer
- > Melanoma
- > Lymphoproliferative disorders and lymphoma

**LEMTRADA**  
alemtuzumab<sup>12mg</sup><sub>IV</sub>